menu
    • menu
    [{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Oncocross","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Tempus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmaceutical Corporation \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CWP291","moa":"Wnt\/beta-catenin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmaceutical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"14-C Epaminurad","moa":"URAT1","graph1":"Undisclosed","graph2":"Phase I","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"JW Pharmaceutical Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JW Pharmaceutical Corporation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by JW Pharmaceutical Corporation

    Menu

    JW Pharmaceutical Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C Epaminurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Mass Balance Recovery & Metabolite Profile in Healthy Male Subjects

                            Details : 14-C Epaminurad is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            June 25, 2025

                            Lead Product(s) : 14-C Epaminurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Marketing Authorization for the Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea

                            Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Tempus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tempus And JW Pharmaceutical Partner for Data-Based Early R&D

                            Details : The collaboration aims to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Tempus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Oncocross

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development

                            Details : The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 27, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Oncocross

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sub-licensing Agreement for Fostamatinib with JW Pharmaceutical Corporation

                            Details : JW Pharma will be responsible for the development and commercialization rights in Korea for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2021

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CWP291

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy

                            Details : CWP291 is a Wnt/beta-catenin inhibitor that is under development as a first-in-class treatment for acute myeloid leukemia, multiple myeloma and stomach cancer.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 17, 2020

                            Lead Product(s) : CWP291

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2012

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed

                            JW Pharmaceutical Corporation

                            South Korea arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2012

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth